26 results on '"Blomain ES"'
Search Results
2. Antiobesity Pharmacotherapy: New Drugs and Emerging Targets.
- Author
-
Kim, GW, Lin, JE, Blomain, ES, and Waldman, SA
- Subjects
OBESITY ,PANDEMICS ,MEDICAL economics ,DRUG therapy ,CARDIOVASCULAR diseases ,PEOPLE with mental illness ,CARE of people ,ANTIOBESITY agents - Abstract
Obesity is a growing pandemic, and related health and economic costs are staggering. Pharmacotherapy, partnered with lifestyle modifications, forms the core of current strategies to reduce the burden of this disease and its sequelae. However, therapies targeting weight loss have a significant history of safety risks, including cardiovascular and psychiatric events. Here, evolving strategies for developing antiobesity therapies, including targets, mechanisms, and developmental status, are highlighted. Progress in this field is underscored by Belviq (lorcaserin) and Qsymia (phentermine/topiramate), the first agents in more than 10 years to achieve regulatory approval for chronic weight management in obese patients. On the horizon, novel insights into metabolism and energy homeostasis reveal guanosine 3′,5′-cyclic monophosphate (cGMP) signaling circuits as emerging targets for antiobesity pharmacotherapy. These innovations in molecular discovery may elegantly align with practical off-the-shelf approaches, leveraging existing approved drugs that modulate cGMP levels for the management of obesity.Clinical Pharmacology & Therapeutics (2013); 95 1, 53-66 advance online publication 13 November 2013. doi:10.1038/clpt.2013.204 [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
3. Improved organ sparing using auto-planned Stanford volumetric modulated arc therapy for total body irradiation technique.
- Author
-
Ngo N, Blomain ES, Simiele E, Romero I, Hoppe RT, Hiniker SM, and Kovalchuk N
- Subjects
- Humans, Child, Radiotherapy Planning, Computer-Assisted methods, Whole-Body Irradiation, Radiotherapy Dosage, Organs at Risk radiation effects, Radiotherapy, Intensity-Modulated methods
- Abstract
Purpose/objectives: To evaluate dosimetric differences between auto-planned volumetric modulated arc therapy (VMAT) total body irradiation (TBI) technique and two-dimensional radiotherapy using anterior-posterial/posterio-anterial beams (2D AP/PA) TBI technique., Methods: Ten pediatric patients treated with VMAT-TBI on Varian c-arm linac were included in this study. VMAT-TBI plans were generated using our in-house developed and publicly shared auto-planning scripts. For each VMAT-TBI plan, a 2D AP/PA plan was created replicating the institution's clinical setup with the patient positioned at extended source to skin distance (SSD) with a compensator to account for differences in patient thickness, 50% transmission daily lung blocks, and electron chest wall boosts prescribed to 50% of the photon prescription. Clinically relevant metrics were analyzed and compared between the VMAT and 2D plans., Results: All VMAT-TBI plans achieved planned target volume (PTV) D90% ≥ 100% of prescription. VMAT-TBI PTV D90% significantly increased (7.1% ± 2.9%, p < .001) compared to the 2D technique, whereas no differences were observed in global D
max (p < .2) and PTV V110% (p < .4). Compared to the 2D plans, significant decreases in the Dmean to the lungs (-25.6% ± 11.5%, p < .001) and lungs-1 cm (-34.1% ± 10.1%, p < .001) were observed with the VMAT plans. The VMAT technique also enabled decrease of dose to other organs: kidneys Dmean (-32.5% ± 5.0%, p < .001) and lenses Dmax (-5.3% ± 8.1%, p = .03); and in addition, for 2 Gy prescription: testes/ovaries Dmean (-41.5% ± 11.5%, p < .001), brain Dmean (-22.6% ± 5.4%, p = .002), and thyroid Dmean (-18.2% ± 16.0%, p = .03)., Conclusions: Superior lung sparing with improved target coverage and similar global Dmax were observed with the VMAT plans as compared to 2D plans. In addition, VMAT-TBI plans provided greater dose reductions in gonads, kidneys, brain, thyroid, and lenses., (© 2023 Wiley Periodicals LLC.)- Published
- 2023
- Full Text
- View/download PDF
4. Effect of Testicular Boost in Children With Leukemia Receiving Total Body Irradiation and Stem Cell Transplant: A Single-Institution Experience.
- Author
-
Blomain ES, Jiang A, Donaldson SS, Agarwal R, Bertaina A, Shyr D, Eisenberg ML, Hoppe RT, Hiniker SM, and Oh J
- Abstract
Purpose: Children with leukemia who receive fractionated total body irradiation (fTBI) with 12 to 13.2 Gy as part of conditioning for hematopoietic stem cell transplant are frequently treated with an additional 4 Gy testicular boost to reduce the risk of testicular relapse. While institutional practices vary, limited data exists regarding whether the 4-Gy testicular boost reduces the risk of relapse and whether it causes toxicity beyond that imparted by TBI. This study compared the survival and endocrine outcomes among the patients who were treated with and without a testicular boost as part of fTBI from 1990 to 2019 at our center., Methods and Materials: We retrospectively reviewed charts of male children with leukemia treated with fTBI as part of a conditioning regimen for stem cell transplant from 1990 to 2019. Reported outcomes included progression-free survival, testicular relapse rate, and overall survival. Gonadal dysfunction and fertility were assessed by comparing the rate of abnormally low testosterone or high luteinizing hormone or follicular stimulating hormone, number of offspring, fertility service use, and abnormal sperm count in the subsequent follow-up period between the testicular boost and nonboost subset., Results: Ninety-three male patients (63 acute lymphoblastic leukemia, 30 acute myeloid leukemia) with a median age of 9 years (range, 1-22) and follow-up of 3.3 years were included. In addition to 12- to 13.2-Gy fTBI, 51 male patients (54%) received a testicular boost to 4 Gy. There was 1 testicular relapse in the boost subset and none in the nonboost subset. Five-year progression-free survival for the boost and nonboost subset was 74% and 66%, respectively ( P = .31). On multivariable analysis, boost was not associated with improved relapse-free survival or overall survival. More patients in the boost subset (35 of 51, 69%) had abnormal serum gonadal blood work compared with the nonboost subset (18 of 42, 43%) ( P = .03)., Conclusions: Omission of testicular boost may be associated with comparable oncologic but improved gonadal endocrine outcomes and should be further studied., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
5. Liquid Biopsies for Molecular Biology-Based Radiotherapy.
- Author
-
Blomain ES and Moding EJ
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor radiation effects, Cell-Free Nucleic Acids radiation effects, Clinical Trials as Topic, Humans, Liquid Biopsy, Neoplasms genetics, Neoplasms pathology, Precision Medicine, Prognosis, Treatment Outcome, Cell-Free Nucleic Acids genetics, Neoplasms radiotherapy
- Abstract
Molecular alterations drive cancer initiation and evolution during development and in response to therapy. Radiotherapy is one of the most commonly employed cancer treatment modalities, but radiobiologic approaches for personalizing therapy based on tumor biology and individual risks remain to be defined. In recent years, analysis of circulating nucleic acids has emerged as a non-invasive approach to leverage tumor molecular abnormalities as biomarkers of prognosis and treatment response. Here, we evaluate the roles of circulating tumor DNA and related analyses as powerful tools for precision radiotherapy. We highlight emerging work advancing liquid biopsies beyond biomarker studies into translational research investigating tumor clonal evolution and acquired resistance.
- Published
- 2021
- Full Text
- View/download PDF
6. A Step Toward Making VMAT TBI More Prevalent: Automating the Treatment Planning Process.
- Author
-
Simiele E, Skinner L, Yang Y, Blomain ES, Hoppe RT, Hiniker SM, and Kovalchuk N
- Subjects
- Humans, Organs at Risk, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Retrospective Studies, Whole-Body Irradiation, Radiotherapy, Intensity-Modulated
- Abstract
Purpose: Our purpose was to automate the treatment planning process for total body irradiation (TBI) with volumetric modulated arc therapy (VMAT)., Methods and Materials: Two scripts were developed to facilitate autoplanning: the binary plug-in script automating the creation of optimization structures, plan generation, beam placement, and setting of the optimization constraints and the stand-alone executable performing successive optimizations. Ten patients previously treated in our clinic with VMAT TBI were used to evaluate the efficacy of the proposed autoplanning process. Paired t tests were used to compare the dosimetric indices of the produced auto plans to the manually generated clinical plans. In addition, 3 physicians were asked to evaluate the manual and autoplans for each patient in a blinded retrospective review., Results: No significant differences were observed between the manual and autoplan global D
max (P < .893), planning target volume V110% (P < .734), kidneys Dmean (P < .351), and bowel Dmax (P < .473). Significant decreases in the Dmean to the lungs and lungs-1cm (ie, lungs with 1-cm inner margin) volumes of 5.4% ± 6.4% (P < .024) and 6.8% ± 7.4% (P < .017), respectively, were obtained with the autoplans compared with the manual plans. The autoplans were selected 77% of the time by the reviewing physicians as equivalent or superior to the manual plans. The required time for treatment planning was estimated to be 2 to 3 days for the manual plans compared with approximately 3 to 5 hours for the autoplans., Conclusions: Large reductions in planning time without sacrificing plan quality were obtained using the developed autoplanning process compared with manual planning, thus reducing the required effort of the treatment planning team. Superior lung sparing with the same target coverage and similar global Dmax were observed with the autoplans as compared with the manual treatment plans. The developed scripts have been made open-source to improve access to VMAT TBI at other institutions and clinics., (Copyright © 2021 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
7. A Preliminary Report of Gonadal-Sparing TBI Using a VMAT Technique.
- Author
-
Blomain ES, Kovalchuk N, Neilsen BK, Skinner L, Hoppe RT, and Hiniker SM
- Subjects
- Female, Humans, Male, Organs at Risk, Prospective Studies, Quality of Life, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Radiotherapy, Intensity-Modulated adverse effects, Whole-Body Irradiation
- Abstract
Reproductive toxicity is common after total body irradiation (TBI) and has major quality of life implications for patients. In that context, this is the first report of gonadal-sparing volumetric-modulated arc therapy (VMAT) TBI, successfully delivered in a boy and a girl with aplastic anemia. Both patients' VMAT TBI plans demonstrated improved gonadal sparing versus simulated conventional 2-dimensional (2D) approach (mean testes dose, 0.45 Gy VMAT vs 0.72 Gy 2D; mean ovary dose, 0.64 Gy VMAT vs 1.47 Gy 2D). Planning target volume coverage was also improved for both cases with the VMAT plan versus conventional 2D plan (2 Gy D90% vs 1.9 Gy D90%, respectively). Given these dosimetric advantages, the present study can serve as a proof-of-concept for further prospective studies evaluating this technique for wider applications in populations receiving TBI., (Copyright © 2020 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
8. APC-β-catenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis.
- Author
-
Blomain ES, Rappaport JA, Pattison AM, Bashir B, Caparosa E, Stem J, Snook AE, and Waldman SA
- Subjects
- Adenomatous Polyposis Coli Protein genetics, Animals, Cell Line, Tumor, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Databases, Genetic statistics & numerical data, Genes, Tumor Suppressor, Humans, Intestinal Mucosa metabolism, Mice, Mice, Knockout, Paracrine Communication, Signal Transduction, Adenomatous Polyposis Coli Protein deficiency, Adenomatous Polyposis Coli Protein metabolism, Colorectal Neoplasms pathology, Gastrointestinal Hormones metabolism, Intestinal Mucosa pathology, Natriuretic Peptides metabolism, Receptors, Enterotoxin metabolism, TCF Transcription Factors metabolism, beta Catenin metabolism
- Abstract
Sporadic colorectal cancer initiates with mutations in APC or its degradation target β-catenin, producing TCF-dependent nuclear transcription driving tumorigenesis. The intestinal epithelial receptor, GUCY2C, with its canonical paracrine hormone guanylin, regulates homeostatic signaling along the crypt-surface axis opposing tumorigenesis. Here, we reveal that expression of the guanylin hormone, but not the GUCY2C receptor, is lost at the earliest stages of transformation in APC-dependent tumors in humans and mice. Hormone loss, which silences GUCY2C signaling, reflects transcriptional repression mediated by mutant APC-β-catenin-TCF programs in the nucleus. These studies support a pathophysiological model of intestinal tumorigenesis in which mutant APC-β-catenin-TCF transcriptional regulation eliminates guanylin expression at tumor initiation, silencing GUCY2C signaling which, in turn, dysregulates intestinal homeostatic mechanisms contributing to tumor progression. They expand the mechanistic paradigm for colorectal cancer from a disease of irreversible mutations in APC and β-catenin to one of guanylin hormone loss whose replacement, and reconstitution of GUCY2C signaling, could prevent tumorigenesis.
- Published
- 2020
- Full Text
- View/download PDF
9. Stereotactic radiosurgery practice patterns for brain metastases in the United States: a national survey.
- Author
-
Blomain ES, Kim H, Garg S, Bhamidipati D, Guo J, Kalchman I, McAna J, and Shi W
- Abstract
Background: Stereotactic radiosurgery (SRS) has emerged as an important modality for the treatment of intracranial metastases. There are currently few established guidelines delineating indications for SRS use and fewer still regarding plan evaluation in the treatment of multiple brain metastases., Methods: An 18 question electronic survey was distributed to radiation oncologists at National Cancer Institute (NCI) designated cancer centers in the USA (60). Centers without radiation oncologists were excluded. Physicians who indicated that they do not prescribe SRS were excluded from the remaining survey questions. Sign test and Chi-square test were used to determine if responses differed significantly from random distribution., Results: One hundred sixteen of the 697 radiation oncologists surveyed completed the questionnaire, representing 51 institutions. Sixty-two percent reported treating patients with brain metastases using SRS. Radiation oncologists prescribing SRS most commonly treat CNS (66.2%) and lung (49.3%) malignancies. SRS was used more frequently for < 10 brain metastases (73.7%; p < 0.0001) and whole brain radiation therapy (WBRT) for > 10 brain metastases (82.5%; p < 0.0001). The maximum number of lesions physicians were willing to treat with SRS without WBRT was 1-4 (40.4%) and 5-10 (42.4%) ( p < 0.0001 compared to 11-15, 16-20 and no limit). The most important criteria for choosing SRS or WBRT were number of lesions ( p < 0.0001) and performance status ( p = 0.016). The most common margin for SRS was 0 mm (49.1%; p = 0.0021). The most common dose constraints other than critical structure was conformity index (84.2%) and brain V12 (61.4%). The LINAC was the most common treatment modality (54.4%) and mono-isocenter technique for multiple brain metastases was commonly used (43.9%; p = 0.23). Most departments do not have a policy for brain metastases treatment (64.9%; p = 0.024)., Conclusions: This is one of the first national surveys assessing the use of SRS for brain metastases in clinical practice. These data highlight some clinical considerations for physicians treating brain metastases with SRS., Competing Interests: Conflict of interest The authors declare that they have no conflict of interest.
- Published
- 2018
- Full Text
- View/download PDF
10. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
- Author
-
Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y, Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, Evans JJ, Judy K, Farrell CJ, and Andrews DW
- Subjects
- Adult, Aged, Brain Neoplasms drug therapy, Disease Progression, Female, Glioma drug therapy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Retrospective Studies, Treatment Failure, Treatment Outcome, Antineoplastic Agents, Immunological therapeutic use, Bevacizumab therapeutic use, Brain Neoplasms radiotherapy, Dose Fractionation, Radiation, Glioma radiotherapy, Neoplasm Recurrence, Local radiotherapy, Salvage Therapy methods
- Abstract
Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.
- Published
- 2018
- Full Text
- View/download PDF
11. Correction to: Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
- Author
-
Shi W, Blomain ES, Siglin J, Palmer JD, Dan T, Wang Y, Werner-Wasik M, Glass J, Kim L, Bar Ad V, Bhamidipati D, Evans JJ, Judy K, Farrell CJ, and Andrews DW
- Abstract
The fourth author's name was incorrect in the initial online publication. The original article has been corrected.
- Published
- 2018
- Full Text
- View/download PDF
12. Guanylyl cyclase C signaling axis and colon cancer prevention.
- Author
-
Pattison AM, Merlino DJ, Blomain ES, and Waldman SA
- Subjects
- Animals, Carcinogenesis, Cell Cycle, Cyclic GMP chemistry, Enterotoxins chemistry, Gastrointestinal Hormones metabolism, Genomics, Homeostasis, Hormones metabolism, Humans, Inflammation, Ligands, Mutation, Natriuretic Peptides metabolism, Paracrine Communication, Receptors, Enterotoxin, Treatment Outcome, Colonic Neoplasms metabolism, Colonic Neoplasms prevention & control, Receptors, Guanylate Cyclase-Coupled metabolism, Receptors, Peptide metabolism, Signal Transduction
- Abstract
Colorectal cancer (CRC) is a major cause of cancer-related mortality and morbidity worldwide. While improved treatments have enhanced overall patient outcome, disease burden encompassing quality of life, cost of care, and patient survival has seen little benefit. Consequently, additional advances in CRC treatments remain important, with an emphasis on preventative measures. Guanylyl cyclase C (GUCY2C), a transmembrane receptor expressed on intestinal epithelial cells, plays an important role in orchestrating intestinal homeostatic mechanisms. These effects are mediated by the endogenous hormones guanylin (GUCA2A) and uroguanylin (GUCA2B), which bind and activate GUCY2C to regulate proliferation, metabolism and barrier function in intestine. Recent studies have demonstrated a link between GUCY2C silencing and intestinal dysfunction, including tumorigenesis. Indeed, GUCY2C silencing by the near universal loss of its paracrine hormone ligands increases colon cancer susceptibility in animals and humans. GUCY2C's role as a tumor suppressor has opened the door to a new paradigm for CRC prevention by hormone replacement therapy using synthetic hormone analogs, such as the FDA-approved oral GUCY2C ligand linaclotide (Linzess™). Here we review the known contributions of the GUCY2C signaling axis to CRC, and relate them to a novel clinical strategy targeting tumor chemoprevention., Competing Interests: Conflict-of-interest statement: Waldman SA is the Chair (uncompensated) of the Scientific Advisory Board of Targeted Diagnostics and Therapeutics, Inc. which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work.
- Published
- 2016
- Full Text
- View/download PDF
13. Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins.
- Author
-
Pattison AM, Blomain ES, Merlino DJ, Wang F, Crissey MA, Kraft CL, Rappaport JA, Snook AE, Lynch JP, and Waldman SA
- Subjects
- Analysis of Variance, Animals, Cyclic GMP metabolism, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Diarrhea metabolism, Disease Models, Animal, Enterotoxigenic Escherichia coli metabolism, Enterotoxins metabolism, Enzyme-Linked Immunosorbent Assay, Escherichia coli Infections physiopathology, Escherichia coli Proteins metabolism, Humans, Mice, Mice, Inbred C57BL, Mice, Transgenic, Receptors, Enterotoxin, Signal Transduction physiology, Bacterial Toxins metabolism, Enterotoxigenic Escherichia coli physiology, Enterotoxins physiology, Escherichia coli Infections microbiology, Intestinal Mucosa metabolism, Receptors, Guanylate Cyclase-Coupled metabolism, Receptors, Peptide metabolism
- Abstract
Enterotoxigenic Escherichia coli (ETEC) causes ∼20% of the acute infectious diarrhea (AID) episodes worldwide, often by producing heat-stable enterotoxins (STs), which are peptides structurally homologous to paracrine hormones of the intestinal guanylate cyclase C (GUCY2C) receptor. While molecular mechanisms mediating ST-induced intestinal secretion have been defined, advancements in therapeutics have been hampered for decades by the paucity of disease models that integrate molecular and functional endpoints amenable to high-throughput screening. Here, we reveal that mouse and human intestinal enteroids in three-dimensional ex vivo cultures express the components of the GUCY2C secretory signaling axis. ST and its structural analog, linaclotide, an FDA-approved oral secretagog, induced fluid accumulation quantified simultaneously in scores of enteroid lumens, recapitulating ETEC-induced intestinal secretion. Enteroid secretion depended on canonical molecular signaling events responsible for ETEC-induced diarrhea, including cyclic GMP (cGMP) produced by GUCY2C, activation of cGMP-dependent protein kinase (PKG), and opening of the cystic fibrosis transmembrane conductance regulator (CFTR). Importantly, pharmacological inhibition of CFTR abrogated enteroid fluid secretion, providing proof of concept for the utility of this model to screen antidiarrheal agents. Intestinal enteroids offer a unique model, integrating the GUCY2C signaling axis and luminal fluid secretion, to explore the pathophysiology of, and develop platforms for, high-throughput drug screening to identify novel compounds to prevent and treat ETEC diarrheal disease., (Copyright © 2016, American Society for Microbiology. All Rights Reserved.)
- Published
- 2016
- Full Text
- View/download PDF
14. Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer.
- Author
-
Blomain ES, Merlino DJ, Pattison AM, Snook AE, and Waldman SA
- Subjects
- Animals, Endoplasmic Reticulum Stress, Humans, Colorectal Neoplasms metabolism, Guanylate Cyclase metabolism, Hormones metabolism, Obesity metabolism, Signal Transduction
- Abstract
Obesity has emerged as a principal cause of mortality worldwide, reflecting comorbidities including cancer risk, particularly in colorectum. Although this relationship is established epidemiologically, molecular mechanisms linking colorectal cancer and obesity continue to be refined. Guanylyl cyclase C (GUCY2C), a membrane-bound guanylyl cyclase expressed in intestinal epithelial cells, binds the paracrine hormones guanylin and uroguanylin, inducing cGMP signaling in colorectum and small intestine, respectively. Guanylin is the most commonly lost gene product in sporadic colorectal cancer, and its universal loss early in transformation silences GUCY2C, a tumor suppressor, disrupting epithelial homeostasis underlying tumorigenesis. In small intestine, eating induces endocrine secretion of uroguanylin, the afferent limb of a novel gut-brain axis that activates hypothalamic GUCY2C-cGMP signaling mediating satiety opposing obesity. Recent studies revealed that diet-induced obesity suppressed guanylin and uroguanylin expression in mice and humans. Hormone loss reflects reversible calorie-induced endoplasmic reticulum stress and the associated unfolded protein response, rather than the endocrine, adipokine, or inflammatory milieu of obesity. Loss of intestinal uroguanylin secretion silences the hypothalamic GUCY2C endocrine axis, creating a feed-forward loop contributing to hyperphagia in obesity. Importantly, calorie-induced guanylin loss silences the GUCY2C-cGMP paracrine axis underlying obesity-induced epithelial dysfunction and colorectal tumorigenesis. Indeed, genetically enforced guanylin replacement eliminated diet-induced intestinal tumorigenesis in mice. Taken together, these observations suggest that GUCY2C hormone axes are at the intersection of obesity and colorectal cancer. Moreover, they suggest that hormone replacement that restores GUCY2C signaling may be a novel therapeutic paradigm to prevent both hyperphagia and intestinal tumorigenesis in obesity., (Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2016
- Full Text
- View/download PDF
15. GUCY2C ligand replacement to prevent colorectal cancer.
- Author
-
Blomain ES, Pattison AM, and Waldman SA
- Subjects
- Colorectal Neoplasms drug therapy, Colorectal Neoplasms pathology, Humans, Ligands, Receptors, Enterotoxin, Receptors, Peptide, Colorectal Neoplasms prevention & control, Receptors, Guanylate Cyclase-Coupled genetics
- Abstract
Despite advances in screening and prevention strategies, colorectal cancer (CRC) remains the second-leading cause of cancer-related death in the United States. Given this continued public health burden of CRC, there is a clear need for improved disease prevention. CRC initiates and progresses over decades, canonically proceeding via a series of stepwise molecular events that turn a normal epithelium into a dysfunctional epithelium, then subsequently into an adenoma, and finally an invasive adenocarcinoma. An emerging paradigm suggests that guanylyl cyclase C (GUCY2C) functions as a tumor suppressor in the intestine, and that the loss of hormone ligands for this receptor causes epithelial dysfunction and represents an important step in the disease process. In that context, GUCY2C ligand replacement therapy has been proposed as a strategy to prevent colorectal cancer, a translational opportunity that is underscored by the recent regulatory approval of the oral GUCY2C ligand linaclotide (Linzess™, Forest Laboratories and Ironwood Pharmaceuticals, Inc.).
- Published
- 2016
- Full Text
- View/download PDF
16. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG.
- Author
-
Kumar S, Singh J, Kedika R, Mendoza F, Jimenez SA, Blomain ES, DiMarino AJ, Cohen S, and Rattan S
- Subjects
- Adult, Aged, Animals, Female, Humans, Immunoglobulins, Intravenous immunology, Male, Middle Aged, Muscle Contraction, Muscle, Smooth metabolism, Muscle, Smooth physiology, Myenteric Plexus cytology, Neurons metabolism, Neurons physiology, Protein Binding, Rats, Rats, Sprague-Dawley, Scleroderma, Systemic therapy, Immunoglobulins, Intravenous therapeutic use, Receptor, Muscarinic M3 immunology, Scleroderma, Systemic immunology
- Abstract
Gastrointestinal dysmotility in systemic sclerosis (SSc) is associated with autoantibodies against muscarinic-3 receptor (M3-R). We investigated the temporal course of the site of action of these autoantibodies at the myenteric neurons (MN) vs. the smooth muscle (SM) M3-R in relation to disease duration, and determined the role of intravenous immunoglobulin (IVIG) in reversing these changes. Immunoglobulins purified from SSc patients (SScIgG) were used to assess their differential binding to MN and SM (from rat colon) employing immunohistochemistry (IHC). Effect of SScIgG on neural and direct muscle contraction was determined by cholinergic nerve stimulation and bethanechol-induced SM contraction. Effects of IVIG and its antigen-binding fragment F(ab')2 on SScIgG binding were studied by enzyme-linked immunosorbent assay (ELISA) of rat colonic longitudinal SM myenteric plexus (LSMMP) lysate and to second extracellular loop peptide of M3-R (M3-RL2). SScIgG from all patients demonstrated significantly higher binding to MN than to SM. With progression of SSc duration, binding at MN and SM increased in a linear fashion with a correlation coefficient of 0.696 and 0.726, respectively (P < 0.05). SScIgG-mediated attenuation of neural and direct SM contraction also increased with disease duration. ELISA analysis revealed that IVIG and F(ab')2 significantly reduced SScIgG binding to LSMMP lysate and M3-RL2. Dysmotility in SSc occurs sequentially, beginning with SScIgG-induced blockage of cholinergic neurotransmission (neuropathy), which progresses to inhibition of acetylcholine action at the SM cell (myopathy). IVIG reverses this cholinergic dysfunction at the neural and myogenic receptors by anti-idiotypic neutralization of SScIgG., (Copyright © 2016 the American Physiological Society.)
- Published
- 2016
- Full Text
- View/download PDF
17. Does obesity promote the development of colorectal cancer?
- Author
-
Blomain ES and Waldman SA
- Subjects
- Animals, Colorectal Neoplasms genetics, Colorectal Neoplasms pathology, Humans, Obesity epidemiology, Receptors, Enterotoxin genetics, Risk Factors, Colorectal Neoplasms etiology, Obesity complications
- Published
- 2016
- Full Text
- View/download PDF
18. A novel CDX2 isoform regulates alternative splicing.
- Author
-
Witek ME, Snook AE, Lin JE, Blomain ES, Xiang B, Magee MS, and Waldman SA
- Subjects
- Animals, CDX2 Transcription Factor, Cell Line, Tumor, Colon cytology, Enterocytes cytology, HEK293 Cells, Homeodomain Proteins genetics, Humans, Hyaluronan Receptors biosynthesis, Hyaluronan Receptors genetics, Membrane Cofactor Protein biosynthesis, Membrane Cofactor Protein genetics, Mice, Mice, Inbred NOD, Nuclear Proteins genetics, Nuclear Proteins metabolism, Protein Isoforms metabolism, Ribonucleoproteins genetics, Ribonucleoproteins metabolism, Serine-Arginine Splicing Factors genetics, Serine-Arginine Splicing Factors metabolism, Alternative Splicing physiology, Colon metabolism, Enterocytes metabolism, Homeodomain Proteins biosynthesis
- Abstract
Gene expression is a dynamic and coordinated process coupling transcription with pre-mRNA processing. This regulation enables tissue-specific transcription factors to induce expression of specific transcripts that are subsequently amplified by alternative splicing allowing for increased proteome complexity and functional diversity. The intestine-specific transcription factor CDX2 regulates development and maintenance of the intestinal epithelium by inducing expression of genes characteristic of the mature enterocyte phenotype. Here, sequence analysis of CDX2 mRNA from colonic mucosa-derived tissues revealed an alternatively spliced transcript (CDX2/AS) that encodes a protein with a truncated homeodomain and a novel carboxy-terminal domain enriched in serine and arginine residues (RS domain). CDX2 and CDX2/AS exhibited distinct nuclear expression patterns with minimal areas of co-localization. CDX2/AS did not activate the CDX2-dependent promoter of guanylyl cyclase C nor inhibit transcriptional activity of CDX2. Unlike CDX2, CDX2/AS co-localized with the putative splicing factors ASF/SF2 and SC35. CDX2/AS altered splicing patterns of CD44v5 and Tra2-β1 minigenes in Lovo colon cancer cells independent of CDX2 expression. These data demonstrate unique dual functions of the CDX2 gene enabling it to regulate gene expression through both transcription (CDX2) and pre-mRNA processing (CDX2/AS).
- Published
- 2014
- Full Text
- View/download PDF
19. Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy.
- Author
-
Merlino DJ, Blomain ES, Aing AS, and Waldman SA
- Abstract
In recent years, the obesity epidemic has developed into a major health crisis both in the United States as well as throughout the developed world. With current treatments limited to expensive, high-risk surgery and minimally efficacious pharmacotherapy, new therapeutic options are urgently needed to combat this alarming trend. This review focuses on the endogenous gut-brain signaling axes that regulate appetite under physiological conditions, and discusses their clinical relevance by summarizing the clinical and preclinical studies that have investigated manipulation of these pathways to treat obesity.
- Published
- 2014
- Full Text
- View/download PDF
20. Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C.
- Author
-
Witek M, Blomain ES, Magee MS, Xiang B, Waldman SA, and Snook AE
- Subjects
- Animals, Antigens, Neoplasm chemistry, Antineoplastic Agents chemistry, Cell Line, Tumor, Colorectal Neoplasms chemistry, Combined Modality Therapy methods, Disease Models, Animal, Enzyme-Linked Immunosorbent Assay, Epitopes chemistry, Humans, Mice, Mice, Inbred BALB C, Neoplasm Transplantation, Receptors, Enterotoxin, Time Factors, Treatment Outcome, Cancer Vaccines chemistry, Colorectal Neoplasms immunology, Colorectal Neoplasms radiotherapy, Immunotherapy methods, Receptors, Guanylate Cyclase-Coupled metabolism, Receptors, Peptide metabolism
- Abstract
Purpose: Radiation therapy (RT) is thought to produce clinical responses in cancer patients, not only through direct toxicity to cancer cells and supporting tumor stroma cells, but also through activation of immunologic effectors. More recently, RT has potentiated the local and systemic effects of cancer immunotherapy (IT). However, combination regimens that maximize immunologic and clinical efficacy remain undefined., Methods and Materials: We evaluated the impact of local RT on adenoviral-mediated vaccination against the colorectal cancer antigen GUCY2C (Ad5-GUCY2C) in a murine subcutaneous tumor model using mouse CT26 colon cancer cells (CT26-GUCY2C). Immune responses were assessed by ELISpot, and clinical responses were assessed by tumor size and incidence., Results: The specific sequence of tumor-directed RT preceding Ad5-GUCY2C IT transformed inactive therapeutic Ad5-GUCY2C vaccination into a curative vaccine. GUCY2C-specific T cell responses were amplified (P<.05), tumor eradication was maximized (P<.01), and tumor volumes were minimized (P<.001) in mice whose tumors were irradiated before, compared with after, Ad5-GUCY2C vaccination. The immunologic and antitumor efficacy of Ad5-GUCY2C was amplified comparably by unfractionated (8 Gy × 1), or biologically equivalent doses of fractionated (3.5 Gy × 3), RT. The antitumor effects of sequential RT and IT (RT-IT) depended on expression of GUCY2C by tumor cells and the adenoviral vaccine vector, and tumor volumes were inversely related to the magnitude of GUCY2C-specific T cell responses. Moreover, mice cured of CT26-GUCY2C tumors by RT-IT showed long-lasting antigen-dependent protection, resisting tumors formed by GUCY2C-expressing 4T1 breast cancer cells inoculated 50 days after CT26 cells., Conclusions: Optimal sequencing of RT and IT amplifies antigen-specific local and systemic immune responses, revealing novel acute and long-term therapeutic antitumor protection. These observations underscore the importance of modality sequence optimization before the initiation of clinical trials of RT and IT to maximize immune and antitumor responses., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
21. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in colorectal cancer.
- Author
-
Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S, Snook AE, Schulz S, and Waldman SA
- Subjects
- Animals, Caco-2 Cells, Colorectal Neoplasms genetics, Colorectal Neoplasms metabolism, Down-Regulation, Epithelial-Mesenchymal Transition genetics, Fibrosis, HCT116 Cells, Humans, Intestinal Mucosa metabolism, Mice, Mice, Inbred C57BL, Mice, Knockout, Receptors, Enterotoxin, Stem Cell Niche genetics, Cell Proliferation, Cell Transformation, Neoplastic genetics, Colorectal Neoplasms pathology, Intestines pathology, Receptors, Guanylate Cyclase-Coupled physiology, Receptors, Peptide physiology, Transforming Growth Factor beta metabolism
- Abstract
Tumorigenesis is a multistep process that reflects intimate reciprocal interactions between epithelia and underlying stroma. However, tumor-initiating mechanisms coordinating transformation of both epithelial and stromal components are not defined. In humans and mice, initiation of colorectal cancer is universally associated with loss of guanylin and uroguanylin, the endogenous ligands for the tumor suppressor guanylyl cyclase C (GUCY2C), disrupting a network of homeostatic mechanisms along the crypt-surface axis. Here, we reveal that silencing GUCY2C in human colon cancer cells increases Akt-dependent TGF-β secretion, activating fibroblasts through TGF-β type I receptors and Smad3 phosphorylation. In turn, activating TGF-β signaling induces fibroblasts to secrete hepatocyte growth factor (HGF), reciprocally driving colon cancer cell proliferation through cMET-dependent signaling. Elimination of GUCY2C signaling in mice (Gucy2c(-/-)) produces intestinal desmoplasia, with increased reactive myofibroblasts, which is suppressed by anti-TGF-β antibodies or genetic silencing of Akt. Thus, GUCY2C coordinates intestinal epithelial-mesenchymal homeostasis through reciprocal paracrine circuits mediated by TGF-β and HGF. In that context, GUCY2C signaling constitutes a direct link between the initiation of colorectal cancer and the induction of its associated desmoplastic stromal niche. The recent regulatory approval of oral GUCY2C ligands to treat chronic gastrointestinal disorders underscores the potential therapeutic opportunity for oral GUCY2C hormone replacement to prevent remodeling of the microenvironment essential for colorectal tumorigenesis., (©2013 AACR)
- Published
- 2013
- Full Text
- View/download PDF
22. Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis.
- Author
-
Blomain ES, Lin JE, Kraft CL, Trela UT, Rock JM, Aing AS, Snook AE, and Waldman SA
- Subjects
- Animals, Anticarcinogenic Agents administration & dosage, Anticarcinogenic Agents pharmacology, Colorectal Neoplasms enzymology, Drug Discovery, Humans, Ligands, Peptides administration & dosage, Peptides pharmacology, Receptors, Enterotoxin, Anticarcinogenic Agents therapeutic use, Colorectal Neoplasms prevention & control, Peptides therapeutic use, Receptors, Guanylate Cyclase-Coupled agonists, Receptors, Peptide agonists
- Abstract
Colorectal cancer (CRC) is a major public health concern, ranking among the leading causes of cancer death in both men and women. Because of this continued burden there is a clear need for improved treatment, and more importantly prevention of this disease. In recent years there is significant evidence to support the hypothesis that guanylyl cyclase C (GCY2C) is a tumor suppressor in the intestine, and that the loss of hormone ligands for this receptor is an important step in the disease process. Thus, ligand replacement therapy has been proposed as a strategy to prevent CRC. Until recently this strategy was not clinically plausible; however, the recent regulatory approval of linaclotide (LINZESS™, Forest Laboratories and Ironwood Pharmaceuticals, Inc.), an oral GUCY2C ligand, has raised the possibility of utilizing this strategy clinically to prevent CRC.
- Published
- 2013
- Full Text
- View/download PDF
23. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells.
- Author
-
Le K, Blomain ES, Rodeck U, and Aplin AE
- Subjects
- Apoptosis, Cell Adhesion, Cell Line, Tumor, Collagen chemistry, Disease Progression, Drug Screening Assays, Antitumor, Enzyme Activation, Extracellular Signal-Regulated MAP Kinases metabolism, Genes, ras genetics, Humans, Indoles chemistry, Mutation, Phosphorylation, Sulfonamides chemistry, Vemurafenib, ras Proteins genetics, Antineoplastic Agents pharmacology, Drug Resistance, Neoplasm, Extracellular Signal-Regulated MAP Kinases drug effects, Indoles pharmacology, Melanoma metabolism, Sulfonamides pharmacology, raf Kinases antagonists & inhibitors
- Abstract
The RAF inhibitor vemurafenib achieves remarkable clinical responses in mutant BRAF melanoma patients. However, vemurafenib is burdened by acquired drug resistance and by the side effects associated with its paradoxical activation of the ERK1/2 pathway in wild-type BRAF cells. This paradoxical effect has driven the development of a new class of RAF inhibitors. Here, we tested one of these selective, non-paradox-inducing RAF inhibitors termed paradox-breaker-04 (PB04) or PLX7904. Consistent with its design, PB04 is able to efficiently inhibit activation of ERK1/2 in mutant BRAF melanoma cells but does not hyperactivate ERK1/2 in mutant RAS-expressing cells. Importantly, PB04 inhibited ERK1/2 phosphorylation in mutant BRAF melanoma cells with acquired resistance to vemurafenib/PLX4720 that is mediated by a secondary mutation in NRAS. Consistent with ERK1/2 reactivation driving the re-acquisition of malignant properties, PB04 promoted apoptosis and inhibited entry into S phase and anchorage-independent growth in mutant N-RAS-mediated vemurafenib-resistant cells. These data indicate that paradox-breaker RAF inhibitors may be clinically effective as a second-line option in a cohort of acquired vemurafenib-resistant patients., (© 2013 John Wiley & Sons A/S.)
- Published
- 2013
- Full Text
- View/download PDF
24. New advances in models and strategies for developing anti-obesity drugs.
- Author
-
Kim GW, Lin JE, Blomain ES, and Waldman SA
- Subjects
- Anti-Obesity Agents therapeutic use, Appetite Depressants therapeutic use, Drug Design, Humans, Life Style, Models, Theoretical, Anti-Obesity Agents pharmacology, Appetite Depressants pharmacology, Cyclic GMP metabolism, Obesity drug therapy, Weight Gain drug effects, Weight Loss drug effects
- Abstract
Introduction: Obesity is a worldwide pandemic. Obesity-related health and economic costs are staggering. Existing strategies to combat obesity through lifestyle improvements and medical intervention have had limited success. Pharmacotherapy, in combination with lifestyle modification, may play a vital role in reversing the disease burden. However, past and current weight-loss medications have had serious safety risks, notably cardiovascular and psychiatric events., Areas Covered: The authors review the strategies for designing new anti-obesity drugs by describing those currently in development. They describe their target, mechanism of action and developmental or regulatory status. Furthermore, they discuss the problem of weight regain following weight loss, and its relevance to the long-term success of anti-obesity pharmacotherapy., Expert Opinion: For weight management drugs to achieve the safety and efficacy required to be impactful, current studies are uncovering and characterizing new targets, including new signaling circuits and hormones regulating appetite and metabolism, and re-evaluating the role of pharmacotherapy in weight management. To avoid the safety failures of many past weight-loss drugs, the models and strategies covered in this article incorporate recent advances in knowledge and technology. We discuss the emergence of cGMP signaling as a potentially transformative target in weight management. Modulating cGMP signaling may represent an ideal goal for an anti-obesity pharmacotherapy, reflecting some of the major themes described in the present review: targeting pathways that are newly realized as relevant for weight management; promoting safety by re-purposing drugs that are safe, proven, and approved for clinical use; and having a synergistic effect on multiple, reinforcing pathways.
- Published
- 2013
- Full Text
- View/download PDF
25. Mechanisms of Weight Regain following Weight Loss.
- Author
-
Blomain ES, Dirhan DA, Valentino MA, Kim GW, and Waldman SA
- Abstract
Obesity is a world-wide pandemic and its incidence is on the rise along with associated comorbidities. Currently, there are few effective therapies to combat obesity. The use of lifestyle modification therapy, namely, improvements in diet and exercise, is preferable over bariatric surgery or pharmacotherapy due to surgical risks and issues with drug efficacy and safety. Although they are initially successful in producing weight loss, such lifestyle intervention strategies are generally unsuccessful in achieving long-term weight maintenance, with the vast majority of obese patients regaining their lost weight during followup. Recently, various compensatory mechanisms have been elucidated by which the body may oppose new weight loss, and this compensation may result in weight regain back to the obese baseline. The present review summarizes the available evidence on these compensatory mechanisms, with a focus on weight loss-induced changes in energy expenditure, neuroendocrine pathways, nutrient metabolism, and gut physiology. These findings have added a major focus to the field of antiobesity research. In addition to investigating pathways that induce weight loss, the present work also focuses on pathways that may instead prevent weight regain. Such strategies will be necessary for improving long-term weight loss maintenance and outcomes for patients who struggle with obesity.
- Published
- 2013
- Full Text
- View/download PDF
26. Dynamic regulation of mitochondrial transcription as a mechanism of cellular adaptation.
- Author
-
Blomain ES and McMahon SB
- Subjects
- DNA, Mitochondrial genetics, DNA, Mitochondrial metabolism, DNA-Directed RNA Polymerases genetics, DNA-Directed RNA Polymerases metabolism, Gene Expression Regulation, Humans, Nuclear Proteins genetics, Oncogene Protein p55(v-myc) genetics, Oncogene Protein p55(v-myc) metabolism, Repressor Proteins genetics, Repressor Proteins metabolism, Steroids metabolism, Adaptation, Biological genetics, Mitochondria genetics, Mitochondria physiology, Nuclear Proteins metabolism, Transcription, Genetic
- Abstract
Eukaryotes control nearly every cellular process in part by modulating the transcription of genes encoded by their nuclear genome. However, these cells are faced with the added complexity of possessing a second genome, within the mitochondria, which encodes critical components of several essential processes, including energy metabolism and macromolecule biosynthesis. As these cellular processes require gene products encoded by both genomes, cells have adopted strategies for linking mitochondrial gene expression to nuclear gene expression and other dynamic cellular events. Here we discuss examples of several mechanisms that have been identified, by which eukaryotic cells link extramitochondrial signals to dynamic alterations in mitochondrial transcription. This article is part of a Special Issue entitled: Mitochondrial Gene Expression., (Copyright © 2012 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.